Vanderbilt University Medical Center: Investigational Glaucoma Drug Studied to Prevent Respiratory Distress in COVID-19 Patients
July 17, 2020
July 17, 2020
NASHVILLE, Tennessee, July 17 -- Vanderbilt University Medical Center issued the following news:
Vanderbilt University Medical Center is evaluating razuprotafib, a drug being investigated for the treatment of glaucoma, in a new randomized, investigational trial for the prevention and treatment of acute respiratory distress syndrome (ARDS) in adult patients with moderate to severe COVID-19.
"We urgently need to find effective treatments for COVID-19, especially for . . .
Vanderbilt University Medical Center is evaluating razuprotafib, a drug being investigated for the treatment of glaucoma, in a new randomized, investigational trial for the prevention and treatment of acute respiratory distress syndrome (ARDS) in adult patients with moderate to severe COVID-19.
"We urgently need to find effective treatments for COVID-19, especially for . . .